The effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on progression of gastric cancer: systematic review and meta-analysis. Issue 10 (9th August 2022)

• Record Type: Journal Article
• Authors: Mehrdad, Seyed Ali; Mirzavi, Farshad; Seyedi, Seyed Mohammad Reza; Asoodeh, Ahmad
• Is Part Of: Anti-cancer drugs. Volume 33:Issue 10(2022)
• Page Start: 983
• Page End: 988
• Publication Date: 2022-08-09
• Subjects: Gastric cancer -- Angiotensin receptor blockers -- angiotensin-converting enzyme inhibitors; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000001345
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : Angiotensin receptor blockers (ARB), as well as angiotensin-converting enzyme inhibitors (ACEI), are mostly used as therapy for hypertension and cardiovascular disease. However, they can increase the risk of cancer progression including gastric cancer. Here we aimed to analyze the assessment between ARB and ACEI on the progression of gastric cancer. Cochrane Library, PubMed and EMBASE were searched for articles and abstracts describing ARBs, ACEIs, and incidence of gastric cancer. Risk ratio, hazard ratio and 95% confidence interval (CI) were extracted from each outcome by using a random-effects model. Six studies met our inclusion criteria. These results demonstrated that there is a significant association between ARB with gastric cancer progression (risk ratio = 0.63; 95% CI, 0.5–0.7; P = 0.00; I 2 = 27.299; df (Q) = 2; Q-value = 2.75). However, there was not any link between ACEIs and gastric cancer development (risk ratio = 1.1; 95% CI, 0.92–1.31; P = 0.26; I 2 = 0.00; df (Q) = 3; Q-value = 1.26). All these findings indicated that using the ARBs has raised the progression of gastric cancer in these patients.